单纯肺结核与肺结核并HIV感染患者的抗结核药物性肝损伤临床特征分析

doi:10.20047/j.issn1673-7210.2023.01.20

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (500 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the clinical characteristics of anti-tuberculosis drug-induced liver injury (ATB-DILI) in patients with simple pulmonary tuberculosis and pulmonary tuberculosis combine with human immunodeficiency virus (HIV) infection. Methods Clinical data of 128 patients with ATB-DILI pulmonary tuberculosis admitted to Kunming Third People’s Hospital from January 2019 to January 2021 were retrospectively analyzed. Among them, 76 patients with simple pulmonary tuberculosis were classified as group A, and 52 patients with pulmonary tuberculosis combine with HIV infection were classified as group B. General data and clinical data of two groups were collected; the severity of ATB-DILI in two groups was analyzed; the occurrence time of ATB-DILI in two groups was recorded. Results Globulin in group B was lower than that in group A (P＜0.05). There were no statistical significances in aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transpeptidase, lactate dehydrogenase, alkaline phosphatase, total protein, albumin, total bilirubin, direct bilirubin, indirect bilirubin, and total bile acid between two groups (P＞0.05). The difference of ATB-DILI degree between two groups was statistically significant (P＜0.05). There was statistical significance in the occurrence time of ATB-DILI between two group (P＜0.05). Conclusion Low protein status is one of the factors for ATB-DILI in patients with pulmonary tuberculosis combine with HIV infection, and ATB-DILI appears earlier in patients with pulmonary tuberculosis combine with HIV infection. Adjusting nutritional status and early application of hepatoprotective drugs may have certain clinical value in preventing ATB-DILI.

Key words： Simple pulmonary tuberculosis Pulmonary tuberculosis combine with HIV infection Anti-tuberculosis drug-induced liver injury Clinical characteristics

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Nihong LIU Honglu SUN Yaping CHEN Yangjun YANG Yan DU Yingrong▲

Cite this article:

LU Nihong LIU Honglu SUN Yaping CHEN Yangjun YANG Yan DU Yingrong▲. Clinical characteristics of anti-tuberculosis drug-induced liver injury in patients with simple pulmonary tuberculosis and pulmonary tuberculosis combine with HIV infection[J]. 中国医药导报, 2023, 20(1): 90-93.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.01.20 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I1/90

[1] Mo X，Xu X，Ren Z，et al. Patients with tuberculous meningitis and hepatitis B co-infection have increased risk for anti-tuberculosis drug-induced liver injury and poor outcomes Infection [J]. Infect Dis（Lond），2020，52（11）：793-800.
[2] 全国第五次结核病流行病学抽样调查技术指导组，2010年全国第五次结核病流行病学抽样调查报告[J].中国防痨杂志，2012，34（8）：485-508.
[3] 中华人民共和国国家卫生和计划生育委员会.WS288～2017肺结核诊断[J].中国感染控制杂志，2018，17（7）：642- 652.
[4] 中华医学会结核病学分会.抗结核药物性肝损伤诊治指南（2019年版）[J].中华结核和呼吸杂志，2019，36（10）：343-356.
[5] 韩晶，李健，臧春鹏，等.我国2016-2018年报告HIV/ AIDS首次随访后的跨省流动情况和抗病毒治疗效果分析[J].中华流行病学杂志，2021，42（1）：126-130.
[6] Ruan QL，Huang XT，Yang QL，et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients：a randomized controlled trial [J]. Clin Microbiol Infect，2021，27（4）：576-582.
[7] 董培玲，李宏静，高冀蓉.药物性肝功能衰竭44例临床特征分析[J].中国医药导报，2017，14（32）：112-115.
[8] Lee MR，Huang HL，Lin SW，et al. Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI [J]. Clin Med，2019，8（6）：8-12.
[9] Gerussi A，Natalini A，Antonangeli F，et al. Immune-Mediated Drug-Induced Liver Injury：Immunogenetics and Experimental Models [J]. Int J Mol Sci，2021，22（9）：4557.
[10] 沈银忠，卢洪洲，陈耀凯，等.人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J].新发传染病电子杂志，2022，7（1）：73-87.
[11] 吴雪琼，范琳.活动性结核病患者免疫功能状态评估和免疫治疗专家共识（2021年版）[J].中国防痨杂志，2022， 44（1）：9-27.
[12] 赵啸，陈婧，周枫，等.北京市2010-2015年艾滋病免费抗病毒治疗免疫学效果分析[J].中国公共卫生，2019， 35（12）：1608-1612.
[13] Gu L，Han Y，Li Y，et al. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China [J]. PLoS One，2015，10（8）：e134-e138.
[14] Huang YS，Sun HY，Chang SY，et al. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection [J]. Hepatol Int，2019，13（4）：431-439.
[15] 何玲，唐简，彭忠田.基于HMGB1-RAGE信号通路研究奥拉米特预防抗结核药物性肝损伤的作用机制[J].中国药房，2021，32（18）：2229-2235.
[16] 周红宇，周昌文.血清球蛋白、胆碱酯酶及其比值与肝硬化肝脏储备功能评估的研究进展[J].临床消化病杂志，2019，31（4）：267-270.
[17] 潘万贵，林毅辉，蒋福亮.血清白蛋白与肝内胆汁淤积症患儿肝肋下肿大程度、凝血功能的相关性分析[J].中国中西医结合儿科学，2021，13（4）：336-339.
[18] 黄德良，戴炜，陈军，等.抗结核药物导致肝损伤的临床特征及危险因素分析[J].临床肝胆病杂志，2021，37（10）：2369-2375.
[19] 陆霓虹，汪亚玲，杨蕤，等.艾滋病并肺结核患者与单纯性肺结核患者免疫功能变化的临床意义[J].昆明医科大学学报，2013，34（2）：153-155.
[20] 李卉，张宏亮，杨天燕，等.我院125例抗结核药物不良反应报告分析[J].中国医药导报，2020，17（29）：151-154.
[21] Goutal S，Auvity S，Legrand T，et al. Validation of a simple HPLC-UV method for rifampicin determination in plasma：Application to the study of rifampicin arteriovenous concentration gradient [J]. J Pharm Biomed Anal，2016，123（10）：173-178.
[22] 张雨，邵玥明，秦婷婷，等.细胞因子在药物性肝损伤中的研究现状及应用价值[J].临床肝胆病杂志，2020，36（8）：1883-1886.